P53 Gain-of-function Mutations Increase Cdc7-dependent Replication Initiation
Overview
Authors
Affiliations
Cancer-associated p53 missense mutants confer (GOF) and promote tumorigenesis by regulating crucial signaling pathways. However, the role of GOF mutant p53 in regulating DNA replication, a commonly altered pathway in cancer, is less explored. Here, we show that enhanced Cdc7-dependent replication initiation enables mutant p53 to confer oncogenic phenotypes. We demonstrate that mutant p53 cooperates with the oncogenic transcription factor Myb and transactivates Cdc7 in cancer cells. Moreover, mutant p53 cells exhibit enhanced levels of Dbf4, promoting the activity of Cdc7/Dbf4 complex. Chromatin enrichment of replication initiation factors and subsequent increase in origin firing confirm increased Cdc7-dependent replication initiation in mutant p53 cells. Further, knockdown of significantly abrogates mutant p53-driven cancer phenotypes and Importantly, high expression significantly correlates with p53 mutational status and predicts poor clinical outcome in lung adenocarcinoma patients. Collectively, this study highlights a novel functional interaction between mutant p53 and the DNA replication pathway in cancer cells. We propose that increased Cdc7-dependent replication initiation is a hallmark of p53 mutations.
Lipogenic enzyme FASN promotes mutant p53 accumulation and gain-of-function through palmitoylation.
Liu J, Shen Y, Liu J, Xu D, Chang C, Wang J Nat Commun. 2025; 16(1):1762.
PMID: 39971971 PMC: 11839913. DOI: 10.1038/s41467-025-57099-9.
Clinical significance and pro-oncogenic function of DBF4 in clear cell renal cell carcinoma.
Chen L, Wu L, Tang M, Cheng Y, Wang K, Zhang J BMC Urol. 2025; 25(1):8.
PMID: 39815239 PMC: 11737091. DOI: 10.1186/s12894-025-01694-x.
Synthetic lethal strategies for the development of cancer therapeutics.
Ngoi N, Gallo D, Torrado C, Nardo M, Durocher D, Yap T Nat Rev Clin Oncol. 2024; 22(1):46-64.
PMID: 39627502 DOI: 10.1038/s41571-024-00966-z.
Wang Z, Zuo C, Fei J, Chen H, Wang L, Xie Y Discov Oncol. 2024; 15(1):717.
PMID: 39592523 PMC: 11599701. DOI: 10.1007/s12672-024-01615-8.
CDC7 Inhibition Potentiates Antitumor Efficacy of PARP Inhibitor in Advanced Ovarian Cancer.
Liu S, Deng P, Yu Z, Hong J, Gao J, Huang Y Adv Sci (Weinh). 2024; 11(45):e2403782.
PMID: 39412086 PMC: 11615783. DOI: 10.1002/advs.202403782.